
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Patients with serious mental illness such as schizophrenia are more likely to report greater impairment in general functioning as a result of trauma, which is why trauma-informed care is so important.



